ABOUT
Antagonist screening assay for CD27/CD70 axis
InvivoGen offers a cellular assay specifically designed for screening antibody-, Fc-fusion protein-, or small-molecule antagonists of the CD27/CD70 immune checkpoint (IC) axis. This assay is comprised of:
- Jurkat-Lucia™ hCD27: Reporter T cells
- Raji-Null: Antigen-presenting cells (APCs)
These paired cell lines allow the mimicking of the CD27-CD70-mediated co-stimulation between T cells and APCs.
CD27 is an immunostimulatory IC and a member of the TNFR (tumor necrosis factor receptor) superfamily. In humans, CD27 is constitutively expressed on most T cells, memory B cells, plasma cells, and Natural Killer cells. Expression of CD70 is tightly controlled and induced transiently in APCs following stimuli exposure, such as TFN-α, irradiation, or TLR agonists [1, 2]. The CD27–CD70 axis pair plays an important role in immune regulation. In concert with the T cell receptor (TCR) crosslinking, it contributes to efficient T cell activation, proliferation, survival, maturation of effector capacity, and T cell memory [1, 2].
Note: If you are interested in a model that allows the mimicking of an immune synapse through T cell receptor (TCR) crosslinking with [HLA::peptide] complexes, along with the CD27-CD70 costimulatory interaction, please contact us.
Assay principle:
This assay relies on the co-culture of Jurkat-Lucia™ hCD27 and Raji-Null cells:
– Jurkat-Lucia™ hCD27 cells stably express cell surface CD27, along with an NF-κB-inducible Lucia luciferase reporter gene.
– Raji-Null cells express the CD70 activating IC ligand.
In the presence of a potent CD27 or CD70 antagonist, the CD27-CD70-mediated activation is blocked and there is no Lucia production. Activation of the reporter T cells can be readily measured using QUANTI-Luc™ 4 Lucia/Gaussia detection reagent (see Figures).
T-cell key features:
- Stable human CD27 surface expression
- Fully functional CD27 signaling pathway
- NF-κB-inducible Lucia luciferase reporter activity
APC key features:
- High surface expression of human CD70
InvivoGen also offers Jurkat-Lucia™ hCD27 cells without Raji-Null cells to measure the potency of agonists of the CD27/CD70 axis.
Read our review on Immune Checkpoint Blockade
References:
1. Jacobs, J. et al. 2015. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther 155, 1-10.
2. Buchan S.L, et al. 2018. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 131(1):39-48.
Disclaimer: These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.
SPECIFICATIONS
Specifications
CD27/CD70
Human
Screening of antibody-based inhibitors of the CD27/CD70 axis
Complete IMDM (see TDS)
Verified using Plasmotest™
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:CD27/CD70 Bio-IC™
-
Cat code:rajkt-cd27
-
Quantity:3-7 x 10^6 cells (x2)
- 1 vial of Jurkat-Lucia™ hCD27 cells
- 1 vial of Raji-Null cells
- 1 ml of Blasticidin (10 mg/ml)
- 1 ml of Zeocin® (100 mg/ml)
- 1 ml of Normocin™ (50 mg/ml)
- 1 tube of QUANTI-Luc™ 4 Reagent (sufficient to prepare 25 ml)
Please note: Both cell lines are sold together.
Shipping & Storage
- Shipping method: Dry ice
- Liquid nitrogen vapor
- Upon receipt, store immediately in liquid nitrogen vapor. Do not store cell vials at -80°C.
Storage:
Caution:
Details
The CD27/CD70 immune checkpoint
The CD27–CD70 axis plays an important role in immune regulation and is considered an immune checkpoint (IC).
The cluster of differentiation CD27 is a member of the TNFR (tumor necrosis factor receptor) superfamily. In humans, CD27 is constitutively expressed on most T cells, memory B cells, plasma cells, and Natural Killer cells [1].
The Cluster of Differentiation CD70 (aka CD27L, TNFSF7) is also a member of the TNFR family and is known as the sole ligand for CD27. Expression of CD70 is tightly controlled and induced transiently in antigen-presenting cells (APCs) following stimuli exposure, such as TFN-α, irradiation, or TLR agonists [2, 3].
The CD27 and CD70 interaction triggers the TRAF2-TRAF6-NF-kB signaling pathway, and in concert with the T cell receptor (TCR) crosslinking, contributes to efficient T cell activation, proliferation, survival, maturation of effector capacity, and T cell memory [2-4].
The CD27/CD70 immune checkpoint in cancer
CD27 is expressed in various types of hematologic cancers. In leukemia, CD27 signaling leads to the induction of different pathways, supporting stemness, tumor cell proliferation, and self-renewal [1]. The efficacy of targeting the CD27/CD70 axis with an agonistic CD27 mAbs was shown in preclinical models of lymphoma, renal cell carcinoma (RCC), breast cancer, and sarcoma [5]. A human mAb directed at CD27 named varlilumab (also CDX-1127, 1F5) has entered clinical trials. It can activate CD27-positive T cells while mediating the killing of CD27-expressing tumor cells [5, 6]. Also, it has successfully completed a phase I/II dose escalation and cohort expansion study (NCT02335918) in combination with nivolumab in different solid malignancies. Further phase I trials with various combinations as well as phase II trials are still ongoing in renal cell carcinoma, squamous cell carcinoma of the head and neck, ovarian and colorectal cancers, and glioblastoma [5].
Constitutive overexpression of CD70 has been described in a range of solid and hematological malignancies, whereby tumor cells have hijacked the CD27-CD70 signaling pathway to facilitate immune evasion in the tumor microenvironment (TME) [7]. They do this by increasing the amount of suppressive regulatory T cells (Tregs), inducing caspase-dependent apoptosis of T cells, and skewing T cells towards exhaustion, to ensure they circumvent the immune response [2]. Additionally, the presence of CD70 on cancer stem cells is a predictive marker for metastasis and poor prognosis [8]. Exploiting CD70-targeting in cancer patients could help eliminate the CD70-expressing cancer cell populations and abrogate the tumor-promoting mechanisms by the CD70-CD27 signaling axis, both in the early stage and advanced disease. Combinatorial approaches with anti-CD70 targeting therapies have proven their potential in both preclinical and clinical settings, using antibody-mediated therapy, chemotherapy, and Chimeric Antigen Receptor (CAR)-T cell therapy [1].
References:
1. Flieswasser, T., Van den Eynde, A., Van Audenaerde, J. et al. 2022. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res 41, 12.
2. Jacobs, J. et al. 2015. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther 155, 1-10.
3. Buchan S.L, et al. 2018. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 131(1):39-48.
4. Sanborn RE, et al., 2022. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer. 10(8):e005147.
5. Starzer AM, Berghoff AS., 2020. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 4 (Suppl 3):e000629.
6. Vitale LA, et al., 2012. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res. 18(14):3812-21
7. Jacobs, J. et al. 2018. Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. Oncoimmunology 7, e1440167.
8. Liu, L. et al. 2018. Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs. Breast Cancer 25, 706-716.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
